Enzo Biochem Inc. Acquisition by Battery Ventures

On June 24, 2025, Enzo Biochem, Inc., a health care company specializing in molecular biology and genetic engineering, announced its acquisition by Battery Ventures. The transaction, valued at approximately $37 million, involves Battery Ventures acquiring Enzo Biochem for $0.70 per share in an all-cash deal. This acquisition price represents a significant premium over Enzo’s recent stock performance, offering a 75% premium to the closing price on April 22, 2025, and a 32% premium to the closing price on June 23, 2025.

Enzo Biochem, Inc., based in Farmingdale, NY, operates within the Life Sciences Tools & Services sector of the Health Care industry. The company is known for its research, development, and manufacturing of health care products, including labeling and detection products for gene sequencing and genetic analysis. These products are sold globally to the life sciences market. Enzo Biochem’s stock is traded on the OTC Bulletin Board, and as of June 22, 2025, its close price was $0.53.

The acquisition follows a comprehensive strategic review conducted by a special committee of Enzo Biochem’s Board of Directors, aimed at maximizing shareholder value. The committee’s efforts culminated in the formation of a newly established entity, Bethpage Parent, Inc., through which Battery Ventures will complete the acquisition.

Steven Pully, Chairman of the Board and a member of the Strategic Committee, emphasized that the transaction is the result of a thorough evaluation process designed to explore all potential avenues for enhancing shareholder value. The acquisition by Battery Ventures, a global, technology-focused investment firm, marks a significant development for Enzo Biochem, Inc., as it transitions under new ownership.

With a market capitalization of $28,290,000 and a negative price-to-earnings ratio of -3.6, Enzo Biochem’s financial metrics reflect the challenges faced by the company prior to the acquisition. However, the premium offered by Battery Ventures underscores the strategic value seen in Enzo Biochem’s offerings and its potential within the life sciences sector.

This acquisition is expected to provide Enzo Biochem with new opportunities for growth and innovation under the stewardship of Battery Ventures, aligning with the investment firm’s focus on technology-driven enterprises.